Teligent Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%

Teligent (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Clobetasol Propionate Cream USP, 0.05%.  This is Teligent’s fourth approval for 2018, and its twenty-third approval from its internally-developed pipeline of topical generic pharmaceutical medicines.

As quoted in the press release:

Based on recent IQVIA data from January 2018, the total addressable market for this product is approximately $125.4 million.

“Clobetasol Propionate Cream USP, 0.05% is Teligent’s fourth FDA approval in 2018,’’ commented Jason Grenfell-Gardner, President and CEO of the Company.  “This shows the continued success of our R&D team and pipeline.  We look forward to launching this product in the second quarter of 2018.”

Mr. Grenfell-Gardner continued, “We now have twenty-eight topical generic pharmaceutical products in the US portfolio, in addition to our four US injectable products.”

Click here to read the full press release.